Table 2.
Demographic and clinical details of the dystonia patients
| Gender | Age (years) | Disease duration (years) | DYT 1 gene status | BFM score pre-op (0–120) | BFM score post-op (0–120) | Medication | DBS parameters | |
|---|---|---|---|---|---|---|---|---|
| 1 | F | 18 | 9 | + | 48 | 0 | Trihexyphenidyl |
R: 4,5-, 3.9v, 60:μs, 130 Hz L: 0,1-, 3.9v, 60:μs, 130 Hz |
| 2 | M | 24 | 16 | − | 73 | 16 | Clonazepam |
R: 4,5-, 3.9 v, 90:μs, 130 Hz L: 0,1-, 3.8 v, 90:μs, 130 Hz |
| 3 | M | 47 | 37 | + | 52 | 24 | Diazepam tetrabenazine |
R: 4-, 3.5v, 90:μs, 130 Hz L: 0,1-, 3.3v, 60:μs, 130 Hz |
| 4 | F | 23 | 12 | − | 53 | 33 | None |
R: 5-, 4.0v, 60:μs, 130 Hz L: 1-, 4.2v, 60:μs, 130 Hz |
| 5 | F | 52 | 36 | + | 29 | 9 | None |
R: 4-, 3.0v, 60:μs, 130 Hz L: 0-, 3.0v, 60:μs, 130 Hz |
| 6 | F | 16 | 7 | + | 20 | 4 | l-Dopa trihexyphenidyl |
R: 4-, 2.9v, 60:μs, 130 Hz L: 0-, 2.9v, 60:μs, 130 Hz |
| 7 | F | 63 | 4 | − | 23 | 1 | l-Dopa trihexyphenidyl |
R: 6-, 4.6v, 90:μs, 130 Hz L: 2-, 4.6v, 90:μs, 130 Hz |
| 8 | F | 54 | 43 | − | 24 | 12 | None |
R: 4-, 3.7v, 60:μs, 130 Hz L: 1-, 3.7v, 60:μs, 130 Hz |
| 9 | F | 36 | 25 | + | 21 | 1 | Trihexyphenidyl |
R: 4-, 4.6v, 90:μs, 130 Hz L: 0-, 4.2v, 90:μs, 130 Hz |
| 10 | M | 62 | 43 | − | 28 | 15 |
Trihexyphenidyl Baclofen clonazepam |
R: 6-, 3.7v, 90:μs, 130 Hz L: 1-, 3.7v, 90:μs, 130 Hz |
| 11 | F | 22 | 15 | + | 51 | 11 |
Trihexyphenidyl Baclofen |
R: 4-, 3.6v, 60:μs, 130 Hz L: 0-, 3.6v, 60:μs, 130 Hz |
| 12 | F | 64 | 50 | − | 46 | 17 | None |
R: 5,6-, 3.5v, 60:μs, 130 Hz L: 1,2-, 3.5v, 60:μs, 130 Hz |
| 13 | M | 62 | 7 | − | 64 | 38 | None |
R: 4,5-, 3.5v, 60:μs, 130 Hz L: 1,2-, 3.5v, 60:μs, 130 Hz |
| 14 | F | 42 | 30 | + | 27 | 7 | None |
R: 5-, 3.5v, 60:μs, 130 Hz L: 1, 3.5v, 60:μs, 130 Hz |